An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition The recent vote by an FDA committee to add two peptides, BP 157 and KPV, to a list allowing specialty pharmacies to dispense them has ignited controversy over the role of science versus market demand in medical decision making.
The peptides have been touted as miracle cures for various ailments, but beneath the surface lies a complex web of conflicting interests, questionable evidence, and disregard for established protocols.
The FDA's own staff had urged caution on both peptides due to concerns about their efficacy and safety.